RxDoctor Payments Data

Amy Javia, MD

Gastroenterology · Allentown, PANPI 1427443654

Payments from drug & device makers

$265in general payments, 2019–2025

Across 8 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$125
  • Regeneron Healthcare Solutions, Inc.$32
  • Ferring Pharmaceuticals Inc.$25
  • Boston Scientific$22
  • Lilly USA, LLC$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$265100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$265 in reported general payments places this provider in the 15th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$183,389
Medicare patients
389
Services billed
6,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$18,363
LinzessLinaclotide11$14,029
MotegrityPrucalopride Succinate21$12,784
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates38$2,569
Pantoprazole Sodium115$2,246
Omeprazole139$1,774
CholestyramineCholestyramine (With Sugar)16$561
Famotidine39$463
Dicyclomine Hcl28$459
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl23$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$19$32,39123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →